These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25342901)

  • 1. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
    Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
    Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):947-52. PubMed ID: 26387930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.
    Gaspar R
    Nanomedicine (Lond); 2007 Apr; 2(2):143-7. PubMed ID: 17716116
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanomedicines: From Bench to Bedside and Beyond.
    Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
    AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond biotechnology: FDA regulation of nanomedicine.
    Miller J
    Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues and concerns in nanotech product development and its commercialization.
    Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I
    J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of effective patents on future innovations in nanomedicine.
    Bosetti R; Vereeck L
    Pharm Pat Anal; 2012 Mar; 1(1):37-43. PubMed ID: 24236712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
    Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
    Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique benefits of nanotechnology to drug delivery and diagnostics.
    McNeil SE
    Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development trend of nanomedicines].
    Kato K
    Yakugaku Zasshi; 2013; 133(1):43-51. PubMed ID: 23292019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Commission-supported development of targeted nanomedicines: did MediTrans make a difference?
    Storm G; Aime S
    Ther Deliv; 2011 Jul; 2(7):861-4. PubMed ID: 22833900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.